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Abstract: Background. Sinonasal squamous cell carcinomas (SCCs) are rare tumors with no etiologic link to tobacco and alcohol, as opposed to other SCCs of the head and neck (HNSCC). Little is known about the genetic changes in sinonasal SCC.
Methods. DNA copy number changes of sinonasal SCC were analyzed by multiplex ligation-dependent probe amplification (MLPA) and microarray comparative genomic hybridization (maCGH), and results were related to clinicopathologic features.
Results. Copy number losses most frequently included genes at 9p21, 13q14, 17p13, 17q21, and 18q11. Frequent gains were observed on 8q24, 11q13, 17q12, 19p13, and 20q11-q13.
Conclusion. The genomic profile of sinonasal SCC showed a number of chromosomal regions with copy number changes similar to those known in HNSCC, in spite of the differences in etiology. Keywords: maxillary sinus; ethmoid sinus; squamous cell carcinoma; microarray CGH; MLPA Sinonasal squamous cell carcinomas (SCCs) are malignant epithelial tumors originating in the respiratory mucosa of the nasal cavities and paranasal sinuses. A wide variety of histologic types of tumors originates in this anatomic area, mostly epithelial (>75%), of which the most common is SCC, accounting for 80% to 90% of all nasal tumors. [1] [2] [3] Sinonasal SCCs are located in a complex anatomic area, close to structures such as the eyes and brain, which is of special relevance for surgery and postoperative treatment, since mutilation and aesthetic deformities are difficult to avoid. 4 Despite improvements in the field of surgery and radiotherapy, patients with these tumors still face a very unfavorable prognosis. In Spain, the incidence is <1 case per 100,000 inhabitants per year, occurring predominantly among men with a mean age of presentation of 50 to 60 years. 2, 5 Its most frequent origin is the nasal cavity, followed by the maxillary sinus, although these numbers are reversed in some publications. 1, 3 The clinical presentation of patients with sinonasal SCC is very insidious, and tumors are often diagnosed at advanced stages. At diagnosis both affected lymph nodes and the presence of distant metastases are uncommon. The overall prognosis is poor, with an overall 5-year survival of 30% to 50%; local recurrence is the main cause of death among patients. 4, 6, 7 Prognosis of sinonasal SCC of the nasal cavities is better than that of sinonasal SCC of the sinuses because of its diagnosis at earlier stages. Advanced T classification, skull base involvement, orbital extension, and local recurrence are predictors of poor survival. The standard therapeutic modality is surgery, followed by radiotherapy in advanced stages. In some cases chemotherapy is used. 4, [6] [7] [8] [9] Little is known about the molecular pathways of sinonasal SCC development. Occupational exposures not only to leather and wood dust but also to several chemicals such as nickel, arsenic, and formaldehyde have been implicated in the etiology of sinonasal SCC. [10] [11] [12] However, tobacco, a strong etiologic factor for the majority of head and neck squamous cell carcinomas (HNSCCs), does not play an important role in sinonasal SCC. 13, 14 Until the present moment, genetic studies on sinonasal SCCs have demonstrated TP53 mutations and p53 overexpression in up to 56% of cases. [15] [16] [17] Kras mutations have been reported, but only in 1% of cases. 18 Bandoh et al 16 suggested that TP53 mutations and a low apoptotic index are associated with poor survival. Cyclooxygenase 2 (COX2) expression was observed in low frequency, which may rule out a possible role for chronic inflammation in sinonasal SCC development. 17 Using loss of heterozygosity analysis, Götte et al 19 have shown losses on chromosomes 3p, 8p, 17p, and 18q. There are very few genome-wide studies on genetic changes in sinonasal SCC. Cytogenetic analyses on small numbers of cases revealed complex karyotypes, with structural aberrations involving many chromosomes. Losses were detected on 6q and gains on 3q and 11q. 20, 21 We have performed a genome-wide screening of copy number abnormalities by multiplex ligation-dependent probe amplification (MLPA) and microarray comparative genome hybridization (maCGH) on a series of 27 sinonasal SCCs, and investigated possible relations between genetic results and the clinical and pathologic characteristics.
MATERIALS AND METHODS
Tumor Specimens. Tissue samples of 27 SCCs of the nasal cavity and paranasal sinuses were obtained from previously untreated patients treated at the Department of Otolaryngology, Hospital Universitario Central de Asturias, between 1989 and 2006, through radical surgery. Patients with primary tumors in the nasal vestibule or septum were excluded because these tumors probably arise from the skin rather than from nasal respiratory mucosa. No patient had previous professional exposure to leather or wood dust or industrial chemicals. Of 27 primary tumor specimens, 20 were obtained from paraffin blocks and 7 from frozen tumor samples. All patients gave their signed informed consent, and the study had received prior approval from the ethics committee of our institution.
Clinical Variables. Of the 27 patients with sinonasal SCC, 17 were men (63%) and 10 were women (37%). The mean age was 65 years (range, 47-85 years). Twenty-three tumors were located in the maxillary sinus (85%) and 4 in the ethmoid sinus (15%). Our series comprised 10 well-differentiated tumors (37%), 6 moderately differentiated tumors (22%), and 11 poorly differentiated tumors (40%). In accord with the T stage of the TNM classification (Union Internationale Contre le Cancer [UICC] TNM classification of malignant tumors), 22 our series consisted of 3 T2 tumors (11%), 8 T3 tumors (30%), 10 T4a tumors (37%), and 6 T4b tumors (22%). If classifying by stage the series consists of 3 tumors in stage II (11%), 8 tumors in stage III (30%), 7 tumors in stage IVa (26%), and 9 tumors in stage IVb (33%). At the time of diagnosis 4 patients had affected lymph nodes (15%) and no patient had distant metastases. The periorbita was affected in 5 patients (18.5%) and another 5 patients (18.5%) had clear orbital invasion. One patient (4%) had intracranial involvement at diagnosis. Nineteen patients (70%) received radiotherapy after radical surgery. The median follow-up time was 16 months (1-211 months). A detailed description of patient and tumor characteristics is given in Table 1 .
DNA Extraction. Tumor DNA was extracted from frozen tissue samples and from paraffin-embedded tissue samples using Qiagen extraction kits (Qiagen GmbH, Hilden, Germany) in accord with the manufacturer's recommendations. MLPA on DNA from frozen tumor tissue was analyzed by comparing to normal reference DNA extracted from blood of healthy donors and MLPA on DNA from paraffin tumor tissue was analyzed by a comparison with normal reference DNA obtained from paraffin blocks of normal tissue.
Special care was taken to obtain high-quality DNA from the formaldehyde-fixed, paraffin-embedded tissues. DNA extracted from archival material can be partly degraded and cross-linked, the extent of which depends on the pH of the formaldehyde and the time of the fixation before paraffin embedding. To improve the quality of the isolated DNA, we have applied an elaborate extraction protocol especially for paraffin tissues, which includes thorough deparaffination with xylene, methanol washings to remove all traces of the xylene, and a 24-hour incubation in 1 mol/L sodium thiocyanate to reduce cross-links. Subsequently, the tissue pellet was dried and digested for 3 days in lysis buffer with high doses of proteinase K (final concentration, 2 lg/lL, freshly added twice a day). With this protocol, most formaldehyde-fixed, paraffin-embedded tissue samples yielded DNA of relatively good quality, with A260/A280 values between 1.7 and 2.0 measured by Nanodrop (Thermo Scientific, Wilmington, DE) and lengths between 2000 and 20,000 base pairs (bp), and these samples were used in MLPA analysis. For maCGH, a technique more sensitive to DNA quality, we performed an additional quality test using the ENZO Bioscore Screening and Amplification kit (Enzo Life Sciences, Lörrach, Germany). The assay consists of an isothermal whole genome amplification reaction using 100 ng of DNA, followed by purification by QIAquick PCR Purification columns (Qiagen) and measurement of the DNA concentration by Nanodrop (Thermo Scientific). Only those samples that gave a total yield of 3.0 were used for maCGH analysis.
Multiplex Ligation-dependent Probe Amplification. The MLPA technique was performed as described in detail previously. 23 Two different kits were used, together analyzing 58 cancer-related genes distributed throughout the genome (kit P005 and P084; MRC-Holland, Amsterdam, The Netherlands). Each probe is composed of 2 parts that hybridize to adjacent target sequences in the DNA. After a ligation step and a polymerase chain reaction (PCR) amplification, each probe gives rise to a product with a unique size between 130 and 480 bp. Briefly, 100 ng DNA was denatured at 98 C for 5 minutes and hybridized with the MLPA probe mixture at 60 C for 16 hours. Ligation of the 2 parts of each probe was performed by a thermostable ligase. All probe ligation products have the same end sequences, and were amplified by PCR using the same primer pair for 60 C 1 minute, 33 cycles of 95 C 30 seconds, 60 C 30 seconds, and 72 C 1 minute, followed by 20 minutes at 72 C and kept cold at 4 C. The products were subsequently analyzed on an ABI Prism 3100 sequencer and by GeneScan v3.7 software (Applied Biosystems, Warrington, UK).
Fourteen control experiments using normal DNA from 7 different donors were used to calculate median reference values and the SD values for every probe. Each tumor sample was analyzed at least twice. For every gene, the relative copy number was calculated by dividing the average relative peak area of the tumor by the median relative peak area of the normal reference samples. We observed that an MLPA experiment analyzing a new normal DNA resulted in relative copy numbers varying between 0.85 and 1.15, including the SD, for each probe. Therefore, we decided that relative copy number values, including the SD, <0.8 were interpreted as losses, >1.2 as gains, and 2.0 as amplifications.
Microarray
Comparative Genome Hybridization. Microarray CGH was performed on 7 fresh samples and 4 paraffin-embedded samples with a good quality of DNA as described previously. 24 Briefly, sample DNA and reference DNA (extracted and pooled from blood of 10 different healthy donors) were differently labeled by random priming. Three hundred nanograms (test) and 300 ng reference DNA were hybridized to a 30,000-oligonucleotide array printed on Codelink activated slides (Amersham Biosciences, Barcelona, Spain). This array contained 29,134 oligonucleotides covering 28,830 unique genes. Hybridization and washing took place for 2 nights in a specialized hybridization chamber (GeneTAC/HybArray12 hybstation; Genomic Solutions/PerkinElmer, Waltham, MA). Images were acquired using a microarray scanner G2505B (Agilent Technologies, Amstelveen, The Netherlands). Analysis and data extraction were quantified by BlueFuse (BlueGnome, Cambridge, UK). The pooled reference DNA served as an internal control of quality. Normalization of the calculated ratios was done against the mode of all ratios. Graphics were plotted using a moving average of log 2 ratios of 5 neighboring clones. Gains and losses were defined as at least in 2 neighboring clones with deviations of 0.2 from log 2 ratio ¼ 0.0. High-level amplification was considered patients developed distant metastases (18%). At the time of writing, a total of 9 patients remained disease-free. The overall 5-year survival was 28%, and the median disease-free survival was 9 months (range, 1-93 months). We found no significant relation between the overall or disease-free survival and clinical parameters such as localization, histologic differentiation, tumor classification, or disruption of the orbit. Intracranial invasion and affected lymph nodes at the time of diagnosis were observed in cases with poor clinical outcome. The main causes of death in our series were recurrences and distant metastases.
Genetic Data. Both MLPA and maCGH analyses showed genetic alterations in all cases studied. Examples of an MLPA and an maCGH results are given in Figures 1 and 2 , respectively. The most recurrent alterations detected by MLPA were losses of BRCA1 and CDH2 (38%), CRK (33%), STCH and RB1 (29%), CDKN2A and IL18 (25%), and IL4 and BCAR (21%); and gains of EMS1 and BCL2L1 (37%), RECQL4, RELA, and ERBB2 (29%), CCND1 (26%), PTPN1 (22%), and MYC (21%). The chromosomal regions where these genes are localized were also most frequently observed by maCGH, which indicated additional hotspots of losses at 2q25, 3p14, 4q21-qter, and 9q13, and gains at 5p15, 6p21, 7p12, and 16p13. All DNA copy number gains and losses identified by MLPA and maCGH are graphically presented in Figures 3 and 4, respectively. High-level amplifications occurring in 2 of the 27 cases were detected by MLPA for EMS1 and CCND1 (11q13, 4 cases), and ERBB2 (17q21, 2 cases). All were confirmed in at least 1 of the 11 cases analyzed by maCGH. Table 2 shows the complete list of amplifications observed both by microarray CGH and by MLPA. Microarray CGH detected 2 other recurring amplicons, at 7p12 (3 cases) and at 11p13 (2 cases). Candidate genes in these localizations are EGFR and CD44, respectively. Unfortunately, these 2 genes were not included in the 58 genes studied by MLPA.
Clinical-Genetic Correlations. The 4 cases with lymph node metastasis at the time of diagnosis showed more complex copy number changes, with virtually all chromosomes involved in gains and losses, and with several high-level amplifications (see maCGH result of case number 26, Figure 2 ). Five of 8 tumors that developed either lymph node or distant metastasis versus 1 of 19 that did not, demonstrated copy number gains of the oncogene PTPN1 at 20q13 (Fisher exact chi-square test, p ¼ .004). To a lesser extent this relation was also seen for gains of oncogenes CCND1 and EMS1 at 11q13 and PTP4A3 at 8q24 (Table 3) . However, neither of these genetic alterations correlated to recurrence or survival. In fact, no single copy number abnormality was associated with overall or disease-free survival as evaluated by Kaplan-Meier analysis.
DISCUSSION
Little is known about the genetic changes involved in the development of sinonasal SCC. To our knowledge, this work is the first to perform a comprehensive, genome-wide study of DNA copy number changes using 2 different techniques in sinonasal SCC. The number of tumors in this study may be low, but considering that sinonasal SCC is a rare malignancy, we believe our results may serve as a starting point in the study of the molecular biology of sinonasal SCC. The epidemiologic, clinical, and pathologic variables studied in 27 patients are similar to those described in previous series published in the literature. 2, 4, 6, 7 The overall survival rate of patients in our series was 28% after 5 years, similar to the Western published series. 4, 6, 7 However, a Japanese study reported a 5-year survival of 67% in T4 tumors. 9 Lymph node metastasis at the time of diagnosis and intracranial invasion decreased the survival significantly, being the most important prognostic clinical factor in sinonasal SCC. As claimed in previous studies, local recurrences and metastases constituted the main cause of deaths, and postoperative radiotherapy significantly increased survival.
The most common malignancy in the head and neck area is SCC, which is strongly associated with exposure to carcinogens such as alcohol and tobacco. Most of these tumors are localized in the larynx, pharynx, and oral cavity; the majority of genetic [26] [27] [28] In contrast to these tumors, sinonasal SCCs are not related to tobacco, but to occupational exposure to wood or leather dust, nickel, arsenic, and formaldehyde. In addition, premalignant lesions have not been described, although it has been claimed that inverted papillomas may be a precursor of sinonasal SCC. 29 Therefore, we expected sinonasal SCCs to have a pattern of DNA copy number abnormalities different from that of HNSCC. However, our combined microarray CGH and MLPA results demonstrated a number of chromosomal regions with copy number abnormalities similar to HNSCC, such as losses at 1p, 3p, 9p, 11qter, 17p, and 18q; gains at 3q, 5p, 7p, 8q, 11q13, and 20q; and also high-level amplifications at 11q13 (CCND1 and EMS1), 7p12 (EGFR), and 11p13 (CD44) have been described before in HNSCC. 27, 28 Two studies concerning the relation between sinonasal SCC and inverted papilloma as possible precursor lesion also suggested that sinonasal SCCs genetically resemble HNSCC. Caruana et al 30 found that human papillomavirus (HPV) is infrequent in sinonasal SCC, as opposed to SCC that originated in an inverted papilloma. HPV is also infrequent in HNSCC, with the exception of tonsillar tumors. Califano and colleagues 31 demonstrated a pattern of loss of heterozygosity (LOH) in sinonasal SCC similar to that in HNSCC, whereas inverted papilloma did not show any LOH. Overall, it would seem that the histologic type of the tumor, squamous cell carcinoma, is more relevant to the pattern of chromosomal gains and losses than etiologic factors involved in tumorigenesis. This idea is further supported by the study of Singh et al, 32 who compared chromosomal aberrations of HNSCC from smokers and nonsmokers but found no significant differences.
Although concerning only 27 cases, univariate statistical analysis of genetic findings to clinical parameters revealed a significant correlation between gain of PTPN1 at 20q13.2 and tumor dissemination (ie, tumors that developed either lymph node or distant metastasis). PTPN1 (or PTP1B) is a nonreceptor protein-tyrosine phosphatase involved in many cellular signaling pathways, including epidermal growth factor receptor (EGFR) and Ras/extracellular signalrelated kinase (ERK). 33 It may function as a suppressor but also as a promotor of neoplastic transformation. Gene amplification and protein overexpression in up to 72% of cases have been reported in breast cancer, especially in Her2/neu-positive tumors. 33 The 20q13 chromosomal region, however, is very gene rich, and there may be other candidate genes explaining the relation to metastasis. Gains and amplifications of the 20q13.2 region have been correlated with lymph node status in gastric cancer, 34 with recurrence in urothelial tumors, 35 and with tumor progression in colorectal carcinoma. 36 This preliminary finding needs to be confirmed in studies with a larger number of cases.
In conclusion, we have shown that sinonasal SCCs have a number of genetic changes in common with HNSCC, in spite of differences in etiology. This may be important with regard to clinical decision making and possibilities for new therapies, such as those directed against EGFR, 37 because an example could be taken from the more prevalent and far more studied HNSCC.
